Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Hepatitis

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 15 articles:
HTML format



Single Articles


    October 2026
  1. MARTINELLO M, Dore GJ
    Shortening treatment to accelerate hepatitis C elimination.
    Lancet. 2026;408:1532-1533.
    PubMed    


  2. FOSTER GR, Dillon J, Halford R
    Hepatitis C-is discrimination preventing elimination?
    Lancet. 2026 Oct 12:S0140-6736(26)01917-3. doi: 10.1016/S0140-6736(26)01917.
    PubMed    


  3. SHEN CF, Chuang JH, Shih CL
    Taiwan's path to hepatitis C elimination.
    Lancet. 2026;408:1449-1450.
    PubMed    


    September 2026
  4. GOEL A, Rungta S, Kumar V, Shalimar, et al
    8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.
    Lancet. 2026 Sep 30:S0140-6736(26)01380-2. doi: 10.1016/S0140-6736(26)01380.
    PubMed     Abstract available


    April 2026
  5. NELSON NP, Ward JW
    Hepatitis A prevention in the USA depends on routine universal childhood vaccination.
    Lancet. 2026 Apr 22:S0140-6736(26)00510-6. doi: 10.1016/S0140-6736(26)00510.
    PubMed    


    January 2026
  6. YANG YT
    A risky rollback on hepatitis B birth dose in the USA.
    Lancet. 2026 Jan 9:S0140-6736(25)02630-3. doi: 10.1016/S0140-6736(25)02630.
    PubMed    


    November 2025
  7. COOKE GS, Walker SA, Barnes E, Thwaites G, et al
    HCV response-guided therapy: is shorter always better? - Authors' reply.
    Lancet. 2025;406:2540.
    PubMed    


  8. XU L, Zhao W
    HCV response-guided therapy: is shorter always better?
    Lancet. 2025;406:2539-2540.
    PubMed    


    May 2025
  9. ROTH H, Aronsohn A
    Innovative strategies to enhance access to HCV therapy.
    Lancet. 2025 May 7:S0140-6736(25)00636-1. doi: 10.1016/S0140-6736(25)00636.
    PubMed    


  10. COOKE GS, Hung LM, Flower B, McCabe L, et al
    Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial.
    Lancet. 2025 May 7:S0140-6736(25)00097-2. doi: 10.1016/S0140-6736(25)00097.
    PubMed     Abstract available


    August 2024
  11. SALEEM SM, Haq Z
    Bridging gaps in vertical transmission of HIV, syphilis, and hepatitis B in India.
    Lancet. 2024;404:428-429.
    PubMed    


    April 2024
  12. TORRES HA, Mustafayev K, Nastoupil LJ, Shelburne SA, et al
    Severe reactivation of seronegative occult hepatitis B after chemotherapy for lymphoma.
    Lancet. 2024;403:1372-1373.
    PubMed    


    March 2024
  13. COUSINS S
    Egypt's hepatitis success story.
    Lancet. 2024;403:1011-1012.
    PubMed    


    February 2024
  14. HUANG S, Zhang X, Su Y, Zhuang C, et al
    Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2024 Feb 19:S0140-6736(23)02234-1. doi: 10.1016/S0140-6736(23)02234.
    PubMed     Abstract available


    September 2023
  15. MARTINELLO M, Solomon SS, Terrault NA, Dore GJ, et al
    Hepatitis C.
    Lancet. 2023;402:1085-1096.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum